May 19, 2025 · Tralokinumab is used to treat moderate-to-severe eczema (atopic dermatitis) in adults and children aged 12 years and older that is not responding well to prescription topical …

ADBRY® (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled …

Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. [3][5] Tralokinumab …

Tralokinumab injection is used to treat eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Tralokinumab is in a …

Tralokinumab, also known as Adtralza®, is a treatment for moderate to severe atopic eczema (also known as atopic dermatitis) in adults and children aged 12 years and older. …

Feb 1, 2025 · Tralokinumab-ldrm injection is used alone or in combination with other medicines (eg, topical corticosteroids) to treat moderate to severe atopic dermatitis in patients who have …

Tralokinumab is a fully human IgG4 monoclonal antibody used to treat moderate to severe atopic dermatitis. Recent studies suggest IL-13 to be the most abundant cytokine in atopic dermatitis …

Oct 27, 2025 · The active substance in Adtralza, tralokinumab, is a type of protein (monoclonal antibody) designed to neutralise IL-13. By neutralising IL-13, tralokinumab prevents IL-13 from …

Oct 20, 2016 · Tralokinumab is a monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic …

ADBRY ® (tralokinumab-Idrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with …